Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palisade Bio Inc.

1.00
+0.08258.99%
Post-market: 0.9350-0.0650-6.50%19:57 EDT
Volume:1.46M
Turnover:1.48M
Market Cap:2.77M
PE:-0.07
High:1.10
Open:0.9600
Low:0.9536
Close:0.9175
Loading ...

Company Profile

Company Name:
Palisade Bio Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
9
Office Location:
7750 El Camino Real,Suite 2A,Carlsbad,California,United States
Zip Code:
92009
Fax:
- -
Introduction:
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.

Directors

Name
Position
James R. Neal
Chairman of the Board
Thomas M. Hallam
Chief Executive Officer, Director
Binxian Wei
Director
Cristina Csimma
Director
Donald Williams
Director
Mary Ann Gray
Director
Robert J. Trenschel
Director
Stephanie C. Diaz
Director

Shareholders

Name
Position
Thomas M. Hallam
Chief Executive Officer, Director
J. D. Finley
Chief Financial Officer
James DeZazzo
Vice President, Intellectual Property
John Rodenrys
Executive Vice President, Chief Technology Officer
Michael J. Dawson
Chief Medical Officer